Verily and OneOncology Announce Collaboration to Advance Cancer Research

Verily, a precision medical technology company of Alphabet, and OneOncology, the national platform for independent oncology practice, have established a strategic partnership that enables more effective clinical trials.As part of the agreement, Verily will integrate the clinical trial management software (CTMS) platform, SignalPath, with all operations in the OneOncology research network, OneR. SignalPath will enable venues to improve their system infrastructure, streamline management processes, and improve collaboration with donors.

“Clinical trial research is core to high-quality cancer care programs,”

“By using technology to create a platform offering from OneR, we can help enhance our partners’ clinical trial programs, which ultimately better democratizes clinical trials, and improves health equity.”

Dr. Davey Daniel, Chief Medical Officer, OneOncology.

SignalPath is the only CTMS that uses next-generation protocol scanning technology to configure and systematize the research protocol workflow in the platform, saving time and some efforts of staff at location. It is designed to improve the cost, complexity and time involved in conducting clinical studies while optimizing quality and time with patients.

“Verily and OneOncology are both committed to transforming the experience for oncology practices participating in research with the latest data and technology,”

“SignalPath delivers on that vision, easing the workflow for oncologists and their staff, so they can focus on delivering the best possible care.”

Dr. Brad Hirsch, Head of Product & Implementation at Verily and co-founder of SignalPath.

This partnership aims to expand research opportunities at community cancer centers, creating opportunities to increase access to and participation in clinical trials for new cancer treatments. There are more than 1,300 cancer drugs in development, but the participation rate in trials in adult cancer patients in the United States is only 6%.OneOncology will continue to work with Verily as it develops connected solutions in its research and care products, including cancer-focused vertical subscriptions to advance cancer research letters.